FDA removes partial hold on Telcyta clinical development

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

FDA removes partial hold on Telcyta clinical development

PALO ALTO, California—Telik, Inc. has announced that the FDA has removed the partial hold on Telcyta (canfosfamide HCl) clinical trials. This action follows a complete review of Telcyta data by the agency and permits the resumption of Telcyta clinical development. Telcyta is a tumor-activated small-molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small-cell lung cancer. FDA placed the hold on development after phase III data showed lower median survival for women with advanced ovarian cancer receiving Telcyta vs standard chemotherapy.

Articles in this issue
MT103, BiTE antibody, enters phase II testing for ALL
Sides dig in as ESA policy debate heats up
Ixempra gets ok for resistant breast cancer
ASCO adds Oncotype DX to marker guideline
Dr. Norton hopes to weed 'molecular' tumor garden
Accelerated approval for Tasigna
Oxidative stress inducer ups survival in advanced melanoma
FDA removes partial hold on Telcyta clinical development
Should all HER2+ pts receive adjuvant trastuzumab?
R-CHOP is standard of care for advanced DLBCL patients
FDA oks Velcade for patients with renal dysfunction
Phase II trials planned for oral methylnaltrexone for chronic pain
GSK and Synta announce STA-4783 collaboration
2007: A tumultuous year for erythropoietic-stimulating agents
MB07133 gets orphan drug status
Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content
Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

Roman Fabbricatore
November 24th 2025
Article

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Tarlatamab Earns Traditional FDA Approval in ES-SCLC

Russ Conroy
November 19th 2025
Article

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Roman Fabbricatore
November 14th 2025
Article

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.